New drugs that receive expedited review by the Food and Drug Administration are being tested on fewer patients, leaving many safety questions unanswered even after they are approved, a study released on Monday in the Journal of the American Medical Association found.
http://www.nbcnews.com/health/fdas-shorter-approval-time-new-drugs-raises-questions-8C11484613
http://www.nbcnews.com/health/fdas-shorter-approval-time-new-drugs-raises-questions-8C11484613
No comments:
Post a Comment